Oxford Biomedica (LON:OXB) Issues Quarterly Earnings Results

Oxford Biomedica (LON:OXB) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported GBX (30.39) EPS for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%.

Oxford Biomedica Price Performance

Shares of Oxford Biomedica stock traded up GBX 10.50 during trading on Thursday, reaching GBX 491.50. 1,454,662 shares of the company’s stock were exchanged, compared to its average volume of 1,108,617. The firm’s 50-day moving average price is GBX 512.48 and its 200 day moving average price is GBX 576.03. The company has a market cap of £594.95 million, a P/E ratio of -18.26 and a beta of 1.09. Oxford Biomedica has a 1-year low of GBX 420 and a 1-year high of GBX 952. The company has a debt-to-equity ratio of 273.08, a quick ratio of 1.67 and a current ratio of 2.21.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a GBX 900 target price on shares of Oxford Biomedica in a report on Tuesday, September 1st. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 595 price objective on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 8.27 price target on shares of Oxford Biomedica in a research note on Tuesday, June 2nd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of GBX 580.85.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.